Thu, May 15, 8:38 PM (59 days ago)
**Phio Pharmaceuticals Corp. (PHIO) Q1 2025 Financial Summary** **Financial Health and Performance:** - **Revenue:** Phio Pharmaceuticals Corp. (PHIO) reported no revenue for Q1 2025, consistent with its clinical-stage status. - **Profit Margins:** The company incurred a net loss of $1,769,000, an improvement from the $2,154,000 loss in Q1 2024. - **Cash Flow:** Net cash used in operating activities decreased by 37% to $1,275,000. Financing activities provided $9,173,000, primarily from equity issuances. - **Earnings Changes:** The net loss per share improved to $0.41 from $0.47 in Q1 2024. **Operational Performance:** - **Operating Expenses:** Total operating expenses decreased by 15% to $1,872,000, driven by reductions in research and development (23% decrease) and general and administrative expenses (7% decrease). - **Trends:** The company continues to focus on its INTASYL® technology and PH-762 clinical trial, with a cost rationalization program in place. - **Uncertainties:** Phio faces substantial doubt regarding its ability to continue as a going concern, with limited cash resources and recurring losses. **Future Operations Impact:** - **Funding:** Phio expects its current cash resources to fund operations into Q2 2026. Future funding will depend on equity offerings, debt, or strategic opportunities. - **Clinical Trials:** The company is advancing its PH-762 trial and has deferred the IND submission for PH-894. - **Market Risks:** Phio may face challenges in maintaining Nasdaq listing requirements and is subject to U.S. and international trade policy changes. **Summary:** Phio Pharmaceuticals Corp. (PHIO) showed improved financial metrics in Q1 2025, with reduced operating expenses and net loss. The company remains focused on its clinical trials and faces uncertainties regarding future funding and market risks.